MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded…
Freedom Auto Haul Announces Nationwide Open and Enclosed Auto Transport Services for Cars, Boats and RVs
Novra Announces $1.3 Million Private Placement
Fab-Form Industries Ltd. Announces Results for the Year Ended 30 June 2026
Opsio Launches Hiveforce, Merging Human Leadership and an AI Workforce